ruboxistaurin mesylate
Small moleculeexperimental
Clinical trial activity
14 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
12
Phase 3
9
Phase 4
0
Earliest trial started May 1, 1999 (NCT00761852)
Timeline
Indications
Mechanism of action
- Protein kinase C betaINHIBITOR
PRKCB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1- Mol. weight
- 468.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL91829 ↗
Also known as
- 13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1h,13h-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2h)-dione
- arxxant
- ly333531
- ly333531
- ly 333531
- ly-333531
- ly-333531
- ly-333531
- ruboxistaurin
- ruboxistaurin
- ruboxistaurin
- ruboxistaurin
- ruboxistaurin
- ruboxistaurin
- ruboxistaurin
- ruboxistaurin mesilate
- ruboxistaurin mesilate hydrate
- ruboxistaurin mesilate monohydrate
- ruboxistaurin mesilate monohydrate
- ruboxistaurin mesilate monohydrate
- ruboxistaurin mesylate
- ruboxistaurin mesylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02769611 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | The Christ Hospital, University of Cincinnati |
| NCT00297401 | Phase 3 | Mar 1, 2006 | Chromaderm, Inc., Heart and Stroke Foundation of Canada |
| NCT00266695 | Phase 3 | Jan 1, 2006 | Chromaderm, Inc. |
| NCT00133952 | Phase 3 | Aug 1, 2005 | Chromaderm, Inc. |
| NCT00190970 | Phase 2 | Oct 1, 2004 | Chromaderm, Inc., Eli Lilly |
| NCT00090519 | Phase 3 | Feb 1, 2004 | Chromaderm, Inc. |
| NCT00482976 | Phase 2 | Dec 1, 2003 | Chromaderm, Inc., Eli Lilly, Joslin Diabetes Center |
| NCT00552227 | Phase 1 | Sep 1, 2002 | Chromaderm, Inc., University of Pennsylvania |
| NCT00044148 | Phase 2 | Jul 16, 2002 | Chromaderm, Inc. |
| NCT00044395 | Phase 3 | Jul 1, 2002 | Eli Lilly |
| NCT00044408 | Phase 3 | Jul 1, 2002 | Chromaderm, Inc., Eli Lilly |
| NCT00044421 | Phase 3 | Jul 1, 2002 | Eli Lilly |
| NCT00604383 | Phase 3 | Mar 1, 2001 | Chromaderm, Inc. |
| NCT00761852 | Phase 2/Phase 3 (Phase 3) | May 1, 1999 | Eli Lilly, Harvard University |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chromaderm, Inc. | For profit | 10 | 10 | 3 | 2001 |
| Eli Lilly | For profit | 6 | 2 | 2 | 1999 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Heart and Stroke Foundation of Canada | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Joslin Diabetes Center | Academic/Hospital | 1 | 0 | 1 | 2003 |
| The Christ Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2002 |
8 organizations
Page 1 / 1